Lubrizol’s Particle Sciences has received patent for a medication delivery device to the tympanic membrane.
Particle Sciences president Rob Lee said: “This latest patent is a clear-cut demonstration of our staff going beyond formulation to help our clients deliver a complete solution. It stems from work we did several years back and adds to the increasing pool of proprietary and public domain approaches Particle Sciences can offer its clients.
“This patent is aimed at providing targeted dosing to the tympanic membrane. We will be looking to partner with our clients on further development and utilization of this invention.”
Lubrizol LifeSciences company, Particle Sciences, is a leading drug delivery CDMO, an integrated provider of drug development services and manufacturing, and is FDA registered and DEA licensed. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nanoparticulates, drug-eluting devices, solid solutions, lyophilization and others.
Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.
The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
Particle Sciences is part of Lubrizol Advanced Materials.
Source: Company Press Release